Lisata Therapeutics moves forward with legal action following Kuva merger termination

Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) said connected Tuesday it has taken decisive enactment pursuing the termination of its merger statement with Kuva Labs and its subsidiary Kuva Acquisition Corp, filing suit to support stockholder interests and moving swiftly to fortify its fiscal position.

The clinical-stage pharmaceutical company, which develops therapies for precocious coagulated tumors, filed the suit successful the Delaware Court of Chancery, alleging Kuva breached the merger statement dated March 6, 2026.

Lisata is seeking damages for the payment of its stockholders, arsenic good arsenic a $2 cardinal termination interest it says it is owed nether the agreement.

The company's committee said it continues to actively measure strategical alternatives to heighten stockholder value, including a imaginable acquisition, merger, reverse merger, different concern combination, plus sales, oregon liquidation and dissolution. Lisata said it volition supply updates erstwhile its committee approves a definitive people of enactment oregon different disclosure becomes warranted.

To sharpen its absorption and sphere currency for this strategical review, Lisata streamlined its workforce, reducing full-time positions by astir 72%, including its enforcement vice president of probe and improvement and main aesculapian serviceman role. The institution said immoderate affected unit whitethorn proceed supporting the enactment arsenic outer consultants.

Lisata's pb merchandise candidate, certepetide, is an investigational cyclic peptide designed to assistance co-administered oregon tethered anti-cancer drugs penetrate coagulated tumors much effectively, utilizing the company's CendR Platform technology.